Arix Bioscience PLC has provided an update on the timing of the proposed Scheme of Reconstruction. The scheme involves the recommended all-share acquisition of Arix's assets by RTW Biotech Opportunities Ltd (RTW Bio) through a subsidiary, to be carried out via a scheme of reconstruction and the voluntary winding-up of Arix. The Circular and notice of the first general meeting will be sent to Arix's shareholders in January 2024, along with the publication of a prospectus by RTW Bio regarding the new RTW Bio shares. The first Arix general meeting is expected to be held in early 2024. Further details and a full timetable will be provided in the Circular. Jefferies is acting as the financial adviser and corporate broker to Arix in connection with the scheme. The announcement also includes important information for US shareholders, stating that the securities referred to in the announcement have not been and will not be registered under the US Securities Act and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration.